It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2015
  5. New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25

May 20, 2015

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25

Otsuka Pharmaceutical Co., Ltd. markets ABILIFY (generic name is aripiprazole), a product with a demonstrated efficacy and safety profile, in 60 countries and regions around the world. Effective May 25, a new dosage form of ABILIFY with the same demonstrated efficacy and safety for schizophrenia patients, ABILIFY extended-release injectable suspension, for intramuscular use, has gone on sale in Japan in 300 and 400 mg vials and in 300 mg and 400 mg pre-filled syringes. It is the first long-acting, partial dopamine agonist injectable available in Japan. The two alternative formulations are the vial (freeze-dried preparation) and the pre-filled, dual chamber syringe that contains the freeze-dried preparation and water for injection in one simple-to-use syringe kit.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases